Astellas secures EU approval for VYLOY in gastric cancer treatment

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    M2 Equitybites (England), September 20, 2024 News, 1pp
  • Additional Information
    • Abstract:
      M2 Equitybites-September 20, 2024-Astellas secures EU approval for VYLOY in gastric cancer treatment (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Pharmaceutical company Astellas Pharma Inc. (TSE:4503) announced on Friday that the European Commission approval for VYLOY (zolbetuximab) in combination with chemotherapy for first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Zolbetuximab is specifically designed to target tumours expressing CLDN18.2, offering a personalized treatment approach...